ReviewCurrent pharmaceutical design2016
Engineered Autonomous Human Variable Domains.
Review in Current pharmaceutical design, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- A side-by-side biophysical comparison of five single-domain antibody scaffolds used for synthetic display libraries.The Journal of biological chemistry · 2026Article
- Isolation and Characterization of Antibodies Against Vascular Cell Adhesion Molecule-1 Reveals Putative Role for Ig-like Domains 2 and 3 in Cell-to-Cell Interaction.International journal of molecular sciences · 2024Article
- Innovative Therapeutic Strategies in Alzheimer's Disease: A Synergistic Approach to Neurodegenerative Disorders.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Construction of Synthetic Antibody Phage Display Libraries.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Recombinant antibodies and their use for food immunoanalysis.Analytical and bioanalytical chemistry · 2022Review
- Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy.Frontiers in immunology · 2022Article
- Exploring the sequence features determining amyloidosis in human antibody light chains.Scientific reports · 2021Article
- Phage Display Technique as a Tool for Diagnosis and Antibody Selection for Coronaviruses.Current microbiology · 2021Review
- Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.Nature chemical biology · 2021Article
- Application of phage display technology for the production of antibodies against Streptococcus suis serotype 2.PloS one · 2021Article
- Bringing the Heavy Chain to Light: Creating a Symmetric, Bivalent IgG-Like Bispecific.Antibodies (Basel, Switzerland) · 2020Article
- Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect.Journal of translational medicine · 2020Article
- Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike.bioRxiv : the preprint server for biology · 2020Article
- Considerations for the Design of Antibody-Based Therapeutics.Journal of pharmaceutical sciences · 2020Review
- PEPOP 2.0: new approaches to mimic non-continuous epitopes.BMC bioinformatics · 2019Article
- Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies.Frontiers in immunology · 2018Article
- Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.Frontiers in immunology · 2018Review
- Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview.Frontiers in immunology · 2017Review
- CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches.Contrast media & molecular imaging · 2017Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe complex multi-chain architecture of antibodies has spurred interest in smaller derivatives that retain specificity but can be more easily produced in bacteria. Domain antibodies consisting of single variable domains are the smallest antibody fragments and have been shown to possess enhanced ability to target epitopes that are difficult to access using multidomain antibodies. However, in contrast to natural camelid antibody domains, human variable domains typically suffer from low stability and high propensity to aggregate.
methodsThis review summarizes strategies to improve the biophysical properties of heavy chain variable domains from human antibodies with an emphasis on aggregation resistance. Several protein engineering approaches have targeted antibody frameworks and complementarity determining regions to stabilize the native state and prevent aggregation of the denatured state.
conclusionRecent findings enable the construction of highly diverse libraries enriched in aggregation-resistant variants that are expected to provide binders to diverse antigens. Engineered domain antibodies possess unique advantages in expression, epitope preference and flexibility of formatting over conventional immunoreagents and are a promising class of antibody fragments for biomedical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.